Thomas Steyer’s C4 Therapeutics CCCC Stock Holding History

Thomas Steyer’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,000	Closed	-$73.6K	–	106
2026 Q1	$73.6K	Hold	28,000	–	–	﹤0.01%	164
2025 Q4	$53.5K	Hold	28,000	–	–	﹤0.01%	150
2025 Q3	$62.2K	Hold	28,000	–	–	﹤0.01%	136
2025 Q2	$40K	Hold	28,000	–	–	﹤0.01%	140
2025 Q1	$44.8K	Hold	28,000	–	–	﹤0.01%	141
2024 Q4	$101K	Hold	28,000	–	–	﹤0.01%	143
2024 Q3	$160K	Hold	28,000	–	–	﹤0.01%	148
2024 Q2	$129K	Hold	28,000	–	–	﹤0.01%	148
2024 Q1	$229K	Buy	+28,000	New	+$217K	﹤0.01%	142

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Thomas Steyer's CCCC Position: Q2 2026 in Review

Thomas Steyer sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 28,000 shares — an estimated $73.6K sold.

Thomas Steyer first reported a position in CCCC in Q1 2024 and held it in 9 quarters. The position peaked at $229K in Q1 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Thomas Steyer reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
Thomas Steyer sold 28,000 C4 Therapeutics shares in Q2 2026, an estimated $73.6K.
Thomas Steyer first reported a position in C4 Therapeutics in Q1 2024 and held it in 9 quarters.
Thomas Steyer's C4 Therapeutics position peaked at $229K in Q1 2024.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.